A tau PET scan, an imaging test that maps clumps of tau protein tied to Alzheimer's, sharpens prediction of who will worsen but cannot separate every dementia alone, often costs $1,800 to $6,000 out of pocket, and works best after simpler tests with a neurologist. For people with mild memory symptoms evaluated for Alzheimer's, a positive result signals much higher short-term risk and helps stage disease and guide care or trial choices.
The test uses a tracer injection plus a brain scan to estimate the density and spread of tangled tau. According to the U.S. Food and Drug Administration in the FDA approval notice, the agency approved Tauvid (flortaucipir F18) on May 28, 2020 for adults with cognitive impairment evaluated for Alzheimer's disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How well does it predict decline?
- What can it miss or overstate?
- How much does it cost and is it covered?
- What should you do next?
How well does it predict decline?
A large international study gives the clearest numbers for prognosis. Among people with mild cognitive impairment, those positive on both amyloid and tau PET faced a 69.9% risk of dementia within five years. Risk fell to 30.4% when tau was negative and to 15.3% when both scans were negative. The pattern also holds after dementia has started. Tau-positive patients with Alzheimer's dementia had a 67.2% three-year risk of a worse dementia rating.
Tau-negative patients had only about a 32-34% risk. According to Diagnostic Imaging reporting a JAMA study of 6,514 participants from 13 countries in the JAMA findings summary, the result supports tau PET for staging and prognosis. In practice, doctors use the result to separate fast-likely decline from slower or uncertain paths. A combined amyloid-plus-tau picture matters more than either test alone. A negative tau scan lowers near-term worry but does not rule out all causes of memory loss.
What can it miss or overstate?
Tau PET is strongest for Alzheimer's-type tau. First-generation tracers have low sensitivity for non-Alzheimer's 4R tau diseases such as progressive supranuclear palsy and corticobasal degeneration. Medical Xpress reporting UCSF findings notes the scan cannot reliably distinguish all dementias alone. Overreading is another limit.
UC San Francisco reports that flortaucipir also sticks to MAO-B, iron deposits, choroid plexus, and basal ganglia. That off-target signal can look like extra tangles where tau is not driving the change. The takeaway is narrow but important. A positive scan in the right clinical setting points toward Alzheimer's biology and higher risk. A positive or unclear scan in an atypical movement or language syndrome needs more work, not a final label.
How much does it cost and is it covered?
Prices are high and often paid directly by families. According to Fujirebio in the modern Alzheimer's diagnosis guide, tau and FDG PET often cost $1,800-$3,000, while amyloid or tau PET list prices commonly reach $3,000-$6,000. Medicare typically covers one amyloid PET during initial workup, not routine tau PET. That gap shapes decisions.
A family may pay thousands for a tau scan that refines prognosis but does not change daily care. Trial screening is an exception, since eligibility may require proof of tau. Ask for the full self-pay price before booking. Ask whether the read, tracer dose, and facility fee are included. Ask whether a blood test or spinal-fluid test could answer the question first.
What should you do next?
Do not start with tau PET alone. Revised Alzheimer's criteria use amyloid plus tau PET to stage disease from amyloid-only through medial-temporal to neocortical spread. Validated plasma p-tau217 blood tests are emerging as cheaper triage before PET, Fujirebio reports.
A neurologist-directed workup usually combines memory testing, MRI, and fluid biomarkers. HelpDementia.com describes reserving tau PET at specialized centers to clarify prognosis or therapy-trial eligibility. That sequence saves money and reduces false leads.
- Start with a cognitive exam, MRI, and blood or spinal-fluid biomarkers
- Use plasma p-tau217 triage when available to decide if PET is needed
- Save tau PET for unclear prognosis, staging, or possible trial entry
- Bring a medication list, symptom timeline, and prior MRI or blood-test results to that visit





